Open Monoclonal Technology announced an pharma alliance with Genmab.
The deal gives Genmab unlimited access to OMT’s three OmniAb platforms, OmniRat, OmniMouse and OmniFlic.
Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for creation of human therapeutic antibodies, naturally optimized human antibodies, and the only company in the world with three transgenic animal platforms, OmniAb.
For further deal information visit Current Agreements (subscription required)
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity